Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 5, 2008 Brian Orelli	Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business.
The Motley Fool February 1, 2005 Stephen D. Simpson	Zimmer Shoots From the Hip Pure-play orthopedic company delivers the goods, but at what cost? Zimmer carries a price tag that would make a value investor's bones ache.
The Motley Fool March 22, 2005 Stephen D. Simpson	Can Biomet Elbow the Competition? The No. 4 player in orthopedics looks to close the gap. No matter what valuation metric you want to look at, Biomet shares look expensive on an absolute basis.
The Motley Fool October 27, 2005 Stephen D. Simpson	Will Smith & Nephew Keep Flexing? This smaller, British, orthopedic company has competitive products, but industry trends could hurt it. However, the entire orthopedic sector is getting pretty interesting from a value perspective.
The Motley Fool July 26, 2007 Ryan Fuhrmann	Zimmer Simmers The maker of hip and knee replacements gets a leg up on the market. Investors, take note.
The Motley Fool July 21, 2006 Stephen D. Simpson	Stryker and the Terror of the Unknown This has been a pretty bad year to be a good medical technology company. Fears about future pricing and the DOJ investigation keep a lid on the entire sector. So, what about that future for Stryker? Investors, take note.
The Motley Fool July 28, 2005 Stephen D. Simpson	Zimmer at a Simmer Strong demand for reconstructive products keeps this orthopedics company limber. Zimmer's 30-plus trailing price-to-earnings ratio still looks high, but it is in line with this industry's current multiples.
The Motley Fool January 27, 2006 Stephen D. Simpson	Lightning Stryker The dust hasn't yet settled on the orthopedic sector, so wise investors should tread lightly with this medical technology company.
The Motley Fool April 28, 2004 Glen Trematore	Zimmer Makes a Family Proud Zimmer Holdings looks strong when compared with other orthopedic/medical device makers.
The Motley Fool July 23, 2010 Jordan DiPietro	Better Health Care Buy: Stryker or Zimmer Holdings? Which stock is a better purchase to consider?
The Motley Fool October 17, 2008 Brian Orelli	Shareholders Slap Stryker A little earnings miss sends the medical technology company down more than necessary.
The Motley Fool September 21, 2005 Stephen D. Simpson	Can Biomet Stay Limber? Concerns about pricing have buffeted the orthopedic space and the No. 4 player in hips and knees. Whatever the case turns out to be, Biomet is probably a bit riskier than average.
The Motley Fool April 21, 2006 Stephen D. Simpson	Stryker Strikes a Chord A solid quarter and generally positive guidance refuels investor enthusiasm.
The Motley Fool July 27, 2006 Stephen D. Simpson	Zimmer Provides Quarterly Information, and More In addition to its quarterly review, the orthopedic company gave some insight into the government probe. Investors, take note.
The Motley Fool April 27, 2006 Stephen D. Simpson	Guidance Brings Zimmer to Its Knees Sales were a little light this quarter, and the company will have to hustle to meet full-year projections. Investors, tread carefully and only buy when there is a fitting margin of safety here.
The Motley Fool July 23, 2009 Robert Steyer	Long Convalescence for Device Makers Orthopedic product specialists Stryker and Zimmer Holdings forecast a slow-motion recovery.
The Motley Fool January 29, 2007 Matthew Crews	Only One Bone to Pick With Stryker With products for wherever you hurt, the med-tech company continues to deliver solid earnings.
The Motley Fool January 30, 2007 Ryan Fuhrmann	Zimmer Implants a New High Investors, the orthopedic designer, developer, and manufacturer isn't cheap, but stellar companies rarely are.
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
The Motley Fool February 9, 2006 Stephen D. Simpson	Growth Not Enough for Smith & Nephew This orthopedic company has market-leading growth, but just not enough cash flow. Investors shouldn't get too excited about these shares.
The Motley Fool October 25, 2007 Billy Fisher	Plenty of Strength in Zimmer Orthopedic manufacturer Zimmer Holdings reports a solid third quarter, but lowers its forecast for Q4.
The Motley Fool July 27, 2006 Stephen D. Simpson	Smith & Nephew: Better Is Good Enough For British medical device company Smith & Nephew investors, better-than-expected is just fine.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool April 27, 2007 Ryan Fuhrmann	Hip Results at Zimmer Holdings The orthopedic-implant and surgical-product maker is impressing investors, and it may just be warming up.
The Motley Fool September 20, 2006 Ryan Fuhrmann	Biomet's Aching Joints Biomet operates in the appealing medical device industry, but current growth trends are giving investors a headache.
The Motley Fool May 2, 2011 Anupama Pattanaik	J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion.
The Motley Fool July 20, 2005 Stephen D. Simpson	Stryker Delivers the Growth Med-tech company Stryker has been a consistent grower for years and shows no signs of slowing down. There will be bumps along the way, but Stryker is an interesting large-cap growth play.
The Motley Fool April 13, 2006 Stephen D. Simpson	A Foolish Baby Shower: Stryker Here is a stock you can be comfortable with buying for your little one with the intention that it would be held for at least 18 years.
The Motley Fool March 31, 2005 Stephen D. Simpson	The DOJ Goes Fishing for Orthopedics The government's industry-wide investigation of orthopedics is more of a buying opportunity than a real threat.
The Motley Fool October 18, 2007 Billy Fisher	An Empire Strykes Back Stryker reports a quarter of double-digit growth in revenue and earnings. Investors, take note.
The Motley Fool July 20, 2007 Ryan Fuhrmann	Stryker Does a Body Good The orthopedics company continues its double-digit growth in an industry with a bright future. Investors, take note.
The Motley Fool October 19, 2005 Stephen D. Simpson	Stryker Still on Target The ever-present 20% growth target will get tougher to hit, but this is a quality medical company. Investors, take note.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool January 27, 2006 Rich Smith	Foolish Forecast: Boning Up on Zimmer With its margins as high as they are, and rising as steadily as they are, you won't be surprised to hear that the medical technology company's shares command premium prices.
The Motley Fool April 26, 2005 Stephen D. Simpson	Growth Is Knee-High Zimmer turns in another fine quarter, with strength in knee implants leading the way.
The Motley Fool March 28, 2006 Stephen D. Simpson	A Surprising Turn at Biomet The large orthopedic company replaces one of its founders. This change doesn't really make the stock dramatically more, or less, attractive than before. Investors, take note.
The Motley Fool June 30, 2005 Stephen D. Simpson	Biomet Wants Your Body Steady growth continues at the #4 orthopedics player. But Biomet shares haven't had a great year so far, hovering close to their 52-week low.
The Motley Fool September 14, 2005 Stephen D. Simpson	Orthopedic Sector Stumbles Already antsy about potential pricing, investors reacted badly to British orthopedic company Smith & Nephew's earnings guidance.
The Motley Fool January 30, 2009 Brian Orelli	Good Luck in 2010, Zimmer Medical device maker Zimmer met analysts expectations in the fourth quarter, but investors weren't impressed with the company's guidance.
The Motley Fool May 17, 2006 S.J. Caplan	A Shapelier Knee Zimmer gains clearance for a female knee-replacement device. The company's new device should certainly be able to boost revenue by being first to exploit the female marketing angle. Investors, take note.
The Motley Fool November 15, 2005 Stephen D. Simpson	Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.
The Motley Fool March 21, 2006 Stephen D. Simpson	Biomet's Stiff Joints Pricing isn't collapsing, but the orthopedics company isn't exactly prospering, either. Investors, beware.
The Motley Fool December 21, 2005 Stephen D. Simpson	Biomet Takes a Bum Knee Company excuses aside, a subpar quarter lends credence to the notion that orthopedics companies are still in a tough spot. Investors, take note.
BusinessWeek May 30, 2005 Michael Arndt	BW 50: A Test Of Zimmer's Agility Artificial joint maker Zimmer Holdings Inc. has the lead in a hot business. But the company faces a Justice probe and price pressures.
BusinessWeek December 6, 2004 Kathleen Kerwin	Knees And Hips -- And Now What? Stryker may need more than artificial joints. Its CEO-to-be is betting on biotech.
The Motley Fool October 18, 2006 Matthew Crews	Stryker Is Steady Eddy How long can Stryker maintain its Steady Eddy persona? Net earnings will decelerate when gross margins peak.
The Motley Fool July 18, 2008 Brian Orelli	What Strikes Against Stryker? High growth isn't enough to impress investors.
The Motley Fool August 18, 2010 David Meier	Stryker: Deflation Fighter Compared to competitors Zimmer and Medtronic, Stryker appears better prepared to handle a deflationary environment.
The Motley Fool August 4, 2006 Stephen D. Simpson	Medtronic's Shock to the System Its guidance cuts rattled the med-tech industry, but long-term trends remain positive. While the going may be tougher now in the ICD space, it's still an attractive long-term opportunity, and investors may want to start looking around for bargains.
The Motley Fool July 28, 2010 Brian Orelli	Amplifying the Risk-Reward Ratio Amplify, Medtronic's latest, gets a mixed reaction at FDA advisory panel meeting.